Cerebral vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
Online mental health platform for therapy, medication management, and psychiatry, San Francisco CA, raised $300M+. Serves anxiety, depression, ADHD, and insomnia.
About
Cerebral is a San Francisco, California-based online mental health company founded in 2020 that offers therapy, psychiatric evaluations, and medication management through a telehealth platform. The company raised over $300 million, achieving unicorn status in 2021 during a period of rapid growth, and serves patients with conditions including anxiety, depression, ADHD, insomnia, and bipolar disorder through a subscription-based access model.\n\nCerebral's model is designed to make psychiatric care and therapy more accessible than traditional in-person services by offering online intake, same-week appointments with licensed clinicians, electronic prescriptions, and medication delivery through pharmacy partners. The platform serves both self-pay and insurance-covered patients, having expanded insurance contracting significantly to reduce cost barriers. Cerebral employs a large clinician workforce of therapists and psychiatric nurse practitioners operating across most US states.\n\nThe company navigated a period of regulatory and reputational scrutiny in 2022–2023 related to prescribing practices and marketing claims, which led to leadership changes, workforce restructuring, and a strategic refocus on clinical quality and compliance. Cerebral has since invested in clinical governance infrastructure, stricter prescribing protocols, and transparent outcomes reporting. The company continues to compete with Talkspace, Done, and Done Global in the online psychiatry and therapy market, and has repositioned around a more clinically rigorous, insurance-first approach following the operational challenges of its hypergrowth phase.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies; processes millions of PA requests annually for specialty and retail prescriptions at no provider cost.
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.